New triple therapy aims to tame type 2 diabetes
NCT ID NCT06290349
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a third drug (DA5221-T) to an existing two-drug combination can improve blood sugar control in adults with type 2 diabetes. About 174 participants who are not meeting their blood sugar goals will receive either the extra drug or a placebo for 24 weeks. The main goal is to see if the triple therapy lowers HbA1c (a key blood sugar measure) more effectively than the two-drug regimen alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital, Yonsei University college of Medicine
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personality type may influence diabetic wound healing – a study investigates
- Can a strong support network help people with diabetic kidney disease take better care of themselves?
- Eye scan may spot hidden blood-flow changes that signal glaucoma risk in diabetes
- Tight glucose control may preserve insulin-making cells in type 2 diabetes
- A quick finger-prick test could spot hidden diabetes in rural villages
- Could chickpea flour bread tame blood sugar spikes?